Browse our anti-EPOR (EPOR) Antibodies

Human Erythropoietin Receptor (EPOR) interaction partners

1. Study reports for the first evidence that EPOR modulates breast cancer cell morphology changes upon tamoxifen treatment, which result in increased formation of cell protrusions and subsequent cell death and, proposes sustained AKT (show AKT1 Antibodies) phosphorylation in EPOR-overexpressing cells as a mechanism that can lead to EPOR-induced tamoxifen resistance.

2. Authors retrospectively investigated whether TFR2 (show TFR2 Antibodies) isoforms and EPOR are differentially expressed in MDS (show PAFAH1B1 Antibodies) patients and whether the expression is associated with patients' clinical outcomes.

3. High EPOR expression is associated with monoclonal gammopathy of undetermined significance and multiple myeloma.

4. EPO (show EPO Antibodies)-mediated EPOR signaling reduced the viability of myeloma cell lines and of malignant primary plasma cells in vitro

5. this study shows that EPO (show EPO Antibodies) could directly promote tumor progression via EPO (show EPO Antibodies) receptor-expressing macrophages

6. No evidence of in vivo activation of the Epo-R in WAT could be documented despite detectable levels of Epo-R mRNA. CONCLUSION: Thus, in contradiction to animal studies, Epo (show EPO Antibodies) treatment within a physiological relevant range in humans does not exert direct effects in a subcutaneous WAT.

7. Our results suggest that EPO (show EPO Antibodies)/EPOR pathway promotes gastric cancer formation, proliferation, migration, and decreases apoptosis

8. These results suggest that both EpoR-positive and EpoR-negative cancer cells could be regulated by exogenous Epo (show EPO Antibodies). However, an increased response to erythropoietin (show EPO Antibodies) was observed in the EpoR-positive cells. Thus, erythropoietin (show EPO Antibodies) increases the risk of tumor progression in colon cancer and should not be used to treat anemia in this type of cancer.

9. Overexpression of EPOR is associated with clear cell renal cell carcinoma (show MOK Antibodies).

10. HIF-1alpha (show HIF1A Antibodies) and EPO-R may be an indicator of the aggressiveness of invasive breast cancers

Mouse (Murine) Erythropoietin Receptor (EPOR) interaction partners

1. CIS (show CISH Antibodies) interacted with phosphorylated EpoR at Y401, which was critical for the activation of STAT5 (show STAT5A Antibodies) and ERK (show EPHB2 Antibodies).

2. these results have revealed that phosphorylation of Tyr (show TYR Antibodies)-343, Tyr (show TYR Antibodies)-460, and Tyr (show TYR Antibodies)-464 in EpoR underlies JAK2 (show JAK2 Antibodies) V617F mutant-induced tumorigenesis.

3. A solution NMR study of the mouse erythropoietin receptor (mEpoR) comprising the transmembrane domain and the juxtamembrane regions reconstituted in dodecylphosphocholine (DPC) micelles.

4. These data indicate that EpoR signaling is associated with cardiac remodeling following chronic iron deficiency.

5. We propose that the CID (show CENPA Antibodies)-dependent dimerization system combined with the EpoR intracellular domain and the Gata1 (show GATA1 Antibodies) gene regulatory region generates a novel peroral strategy for the treatment of anemia.

6. transmembrane domain and the juxtamembrane region of the erythropoietin receptor in micelles

7. EpoR and its activity are downstream effectors of Klotho (show KL Antibodies) enabling it to function as a cytoprotective protein against oxidative injury.

8. Expression of EPOR in rod photoreceptors, Muller cells, and amacrine, horizontal, and ganglion cells of the peripheral retina is not required for the maturation, function, and survival of these cells in aging tissue.

9. Data indicate a Cbl (show CBL Antibodies)/p85 (show ECM1 Antibodies)/epsin-1 (show EPN1 Antibodies) pathway in erythropoietin receptor (EpoR) endocytosis.

10. Data from knockout mice suggest that adipose tissue-specific disruption of EPO (show EPO Antibodies) receptor does not alter adipose tissue expansion, adipocyte morphology, insulin (show INS Antibodies) resistance, inflammation, or angiogenesis.